Biocytogen Pharmaceuticals (Beijing) (2315.HK) Earnings Analysis
Biocytogen Pharmaceuticals (Beijing) (2315.HK) next reports earnings on 2026-09-02. It has beaten estimates in 0/1 recent quarters (0%). Trailing P/E 104.20.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 2315.HK next report earnings?
| Next earnings date | 2026-09-02 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | 0.84B |
2315.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-08-28 | 0.1315 HKD | n/a | n/a | n/a |
| 2024-08-28 | -0.13968 HKD | -0.12893 HKD | -8.3% | Miss |
Beat rate: 0/1 (0%) over reported quarters with consensus data.
2315.HK valuation and analyst view
| Trailing P/E | 104.20 |
|---|---|
| Trailing EPS | 0.43292 HKD |
| Price / book | 8.26 |
| Dividend yield | 0.00% |
| Market cap | 21.05B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Biocytogen Pharmaceuticals (Beijing) (2315.HK)'s next earnings date?
Biocytogen Pharmaceuticals (Beijing) is next scheduled to report on 2026-09-02 and revenue estimate of 0.84B.
Did 2315.HK beat earnings last quarter?
Consensus estimate data was not available for 2315.HK's 2025-08-28 report.
What is 2315.HK's earnings track record?
Over the last 1 reported quarters with consensus data, 2315.HK beat estimates 0 times (0%).
What is 2315.HK's current P/E ratio and EPS?
2315.HK trades at a trailing P/E of 104.20 on trailing EPS of 0.4329152461032404 HKD.
What do analysts rate 2315.HK?
2315.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.